Despite recent advances in understanding of the pharmacokinetics and electrophysiologic effects of cardiac glycosides, digitalis toxicity remains distressingly common in clinical practice. Another substantial group of patients is markedly underdigitalized, failing to gain the full therapeutic benefits of optimal use of these drugs. Since cardiac digitalis toxicity is a dose-related phenomenon, and serum or plasma digoxin and digitoxin concentrations rise with increasing doses, at least a statistical correlation between circulating levels and clinical state might be expected. Increasing availability of serum or plasma digitalis concentration measurements thus offers the clinician a potential means of improving the patient's chances of benefiting from treatment with cardiac glycosides. Assay methods in current use include a double-isotope dilution derivative method (digitoxin), red cell 86Rb-uptake inhibition (digitoxin and digoxin), Na +-K + ATPase inhibition (digitoxin), ATPase enzymatic displacement (digitoxin and digoxin), gas chromatography (digoxin), and radioimmunoassay (digitoxin, digoxin, and ouabain). The rapidly expanding literature reporting clinical experience with these technics reflects general agreement that mean serum or plasma digoxini and digitoxin levels are significantly higher in patients with clinical evidence of toxicity compared with nontoxic patients. Nevertheless, multiple factors influence individual respinses, and blood level data must be interpreted in the overall clinical context. Hypokalemia, hypercalcemia, hypomagnesemia, acid-base disturbances, hypoxemia, and hypothyroidism all tend to decrease tolerance to any given digitalis dose or blood level. Autonomic nervous system tone and other drugs concurrently received must also be considered. Advanced heart disease in general, and coronary artery disease in particular, appear to predispose patients to apparent digitalis toxicity at relatively lower serum or plasma levels.
CONTRIBUTION OF DIGITALIS ASSAY TECHNICS
Finally, there is growing evidence implicating Na + -K + activated "transport" ATPase as a mediator of digitalis action on the heart.25 28 Experiments with the squid giant axon29 and with red blood cells30 indicate that this cell membrane-bound enzyme is accessible only to digitalis present at the external cell surface. Thus it may be that the digitalis receptor is in relatively close proximity to the extracellular compartment, which would tend to enhance the translation of plasma concentration to myocardial effect.
Animal experimental studies have demonstrated a significant correlation between serum digoxin concentration and electrophysiologic effects as reflected by both acetylstrophanthidin tolerance and repetitive ventricular responses to low-energy endocardial stimuli.31
Digitalis Assay Technics
Recent advances in the ability to quantitate accurately and conveniently the minute serum or plasma concentrations of digitalis glycosides in patients on usual doses of these drugs32 have opened new avenues of investigation. The various approaches which have proven useful in quantitating circulating concentrations are listed in table 1. The limited sensitivity of the duck-embryo bioassay33' 34 led investigators to obtain 14C_ or Hlabeled compounds, allowing the extremely useful studies of Okita,35 Doherty,36 Marcus,37 The relationship between blood levels of digitalis glycosides in patients with and without clinical evidence of toxicity is at once one of the most difficult and most interesting Table 2 summarizes the digoxin findings from a number of laboratories. These series comprise a total of about 1000 patients studied. Mean levels in toxic patients tend to be about twofold higher than those in patients without evidence of toxicity, and the difference was statistically significant in all studies except that of Fogelman and his co-workers.69 Significant overlap between toxic and nontoxic levels has been the general experience, probably related in large part to the various factors affecting myocardial sensitivity just mentioned. In addition, since there are no absolute clinical criteria which unequivocally define digitalis toxicity, at least part of the overlap is probably due to the uncertainties of assignment of patients to "toxic" or "nontoxic" groups. In any case, this overlap demands that serum or plasma levels of digitalis glycosides be evaluated in the clinical context, taking into account all variables which bear on the emergence of toxicity. Intermediate serum digoxin concentrations around 2 ng/ml are particularly likely to be encountered in patients with equivocal signs of digoxin excess such as first-degree atrioventricular (A-V) block or occasional ventricular premature beats.14 Table 3 summarizes studies of the relationship between digitoxin levels and presence or absence of toxicity. Again, significant differences in mean concentrations were generally observed in patients with and without electrocardiographic evidence of toxicity. If anything, the degree of overlap in levels of nontoxic and toxic patients tends to be greater than in the case of digoxin, perhaps related at least in part to the greater extent of plasma protein binding of digitoxin71 and hence greater opportunity for this variable to affect the distribution of the drug in the body
It is important to note that nearly all of the data cited in these studies are from patients with cardiac disease. In our own experience, advanced cardiac disease has been especially Circulation, Volume XLVI, July 1972 prevalent in patients with clinical evidence of toxicity. In the prospective study of patients admitted to Boston City Hospital, 74% of toxic patients were in functional class III or IV as opposed to 54% of nontoxic patients.2 It is generally agreed, then, that no arbitrary set of levels can be selected which clearly separate toxic from nontoxic patients. Although uncommon, patients with digoxin levels below 1.0 ng/ml occasionally meet usual criteria for toxicity. In the presence of cardiac and/or pulmonary disease, a number of factors tend to increase the slope of phase 4 spontaneous diastolic depolarization in specialized conduction tissues,73 74 increase disparity of recovery times (enhancing probability of reentrant rhythm disturbances),7 5 or to depress A-V conduction.73 Since cardiac glycosides tend to produce all of these same electrophysiologic effects,7-78 it is not surprising that these drugs may precipitate clinical toxicity in hearts precariously balanced by cardiopulmonary disease.
An apparent example of this sort of phenomenon is the recent experience of Morrison and Killip,79 who found that hypoxemia associated with chronic lung disease tended to predispose patients to digitalis toxic rhythm disturbances at serum glycoside concentrations lower than those associated with toxicity in a population without advanced hypoxemia.
For reasons which remain unclear, occasional patients with supraventricular tachyarrhythmias such as atrial flutter or atrial fibrillation require serum digoxin concentrations of 3 ng/ml or more to maintain a therapeutically adequate degree of A-V block and sustain these relatively high levels without overt evidence of toxicity.
A intrinsic disease of the A-V conduction system with slow ventricular rates on or off digitalis, the overall correlation between serum digoxin concentration and ventricular rate was poor. However, when the evaluation was restricted to patients who were capable of responding with a rapid rate (and hence had reasonably normal A-V conduction systems), the much better correlation shown in figure 1 resulted.
Acute coronary artery disease has long been suspected to predispose to digitalis toxicity. 80 Based A somewhat more striking result was obtained when patients at the extremes of the overlapping range of serum levels were evaluated as a group. A total of 40 patients had rhythm disturbances consistent with digitalis toxicity at relatively low serum concentrations, or had no signs or symptoms of toxicity at relatively high levels. Of the 16 "toxic'> patients with digoxin levels < 1.0 or digitoxin levels < 10 ng/ml, 15 (91%) had coronary artery disease. On the other hand, of 24 nontoxic patients with serum levels of digoxin > 2.0 or digitoxin . 26 ng/ml, only 11 (46%) had coronary disease. This difference is statistically significant, with a P value less than 0.01. Thus, coronary artery disease in particular appears to predispose occasional patients to rhythm disturbances due to (or closely mimicking) digitalis excess at relatively low serum levels.
Two other types of patients bear mention who appear to differ from the bulk of digitalized adult patients with cardiac disease. One of these groups is encountered in pediatric practice, where relatively large doses of digoxin on a milligram per kilogram basis are routinely given to infants with congenital heart disease. These doses result in relatively high blood levels, which are generally quite well tolerated in this younger age group.83, 84 Young adults with normal hearts also tolerate remarkably large doses or serum concentrations of digoxin, as we have observed in our experience with accidental and suicidal ingestions. 85 An objective approach to the evaluation of the problem of sensitivity of the heart to increments of digitalis is the acetylstrophanthidin tolerance test. In contrast with normal subjects, poor and erratic gastrointestinal absorption of digoxin has been documented in patients with malabsorption syndromes and steatorrhea.4 Patients with sprue, short bowel syndromes, radiation enteritis, and marked hypermotility showed low serum digoxin concentrations on usual oral maintenance digoxin doses. Patients with maldigestion due to pancreatic insufficiency, on the other hand, had values close to the usual range.
A particularly enlightening study has been carried out by Lindenbaum et al. 15 Because relatively large oral doses of digoxin had been required to manage certain patients adequately, they used a radioimmunoassay method to study the absorption of digoxin produced by different manufacturers. The brand studied by White et al.90 gave a very similar curve of serum levels after an oral dose, but the other preparations studied gave lower values despite comparable amounts of total digoxin present in all tablets. One preparation gave a peak An interesting variation in the usual time course of the decline of serum digoxin concentration has been observed by radioimmunoassay in patients following large accidental or suicidal ingestions of digoxin.85 Apparent serum half-times between 5 and 48 hours after ingestion were substantially shorter than those observed with ordinary doses of digoxin, increasing to the usual range only when the serum level had fallen to 2 ng/ml or less.
Serum digitoxin concentration measurements by the red cell 86Rb-uptake inhibition technic and by direct measurement of tritiated digitoxin. 96 We have recently been interested in learning more about some of the shorter acting cardiac glycosides such as ouabain. The plasma pharmacokinetics of ouabain have been defined by radioimmunoassay in dogs and in normal human subjects.97 After 67 hours, an exponential decline in plasma ouabain concentration with a half-life of 21 hours is reached in human subjects. This value is in good agreement with prior estimates of pharmacologic half-life based on ventricular rate responses of patients in atrial fibrilliation98 and estimates of half-life of positive inotropic effect studied by systolic time intervals. 99 Thus, the duration of effect of ouabain, like digoxin and digitoxin, bears a close relationship to the half-life of serum or plasma concentration after blood-tissue equilibrium has been reached. 
